PATENT CLAIM ANALYSIS

Application Number: 16094644
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-04
Patent Classification: ["424", "470000"]

Abstract:
Described herein are pharmaceutical compositions for the oral administration of mesalazine, as well as methods of making such pharmaceutical compositions, and therapeutic methods for using them. The compositions comprise delayed-immediate release and delayed-extended release formulation of mesalazine.

Claim (Index 64):
A method of treating inflammatory bowel disease, such as ulcerative colitis and mild-to-moderate Crohn's disease, comprising orally administering to the subject a unit dose pharmaceutical product according to  claim 42 .

Metadata:
- Claim Count in Document: 8.0
- Percentile: 97.0
- Lexical Diversity: 1.46429
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15076253', '14255529', '14589839', '14230067', '14841428']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7352587380737226
- 35 USC 102 Novelty (BERT): 0.5264702285874073
- Combined Prediction Score: 0.714379887125091
- Mean Citation Score: 313.1899160000001
- Max Citation Score: 319.44415
- Similarity Product: 165.14027460478542

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test